Cancer of Unknown Primary Site Active Not Recruiting Phase 2 Trials for Cobimetinib (DB05239)

IndicationStatusPhase
DBCOND0089665 (Cancer of Unknown Primary Site)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03498521
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteTreatment